The Part 11 Controversy: A Root Cause Analysis and Science-Based Solutions

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-06-01-2005, Volume 205 Supplement, Issue 3

The confusion surrounding the application of 21 CFR Part 11 can be solved by focusing on the common rationale that both protects the public health and drives the fundamental basis of the industry's business: good science.

Related Content:

Quality SystemsInformation TechnologyPharmaceutical Technology-06-01-2005
FDA Reports on Status of Postmarketing Requirements and Postmarketing Commitments
Novartis’ Radioligand Therapy Gains FDA Nod for Pediatric Patients
Navigating an Uncertain Regulatory Environment for mRNA-based Products